This inventor holds 3 USPTO granted patents. Top assignees: Yonsei University, Kanazawa University, Samsung Electronics Co., Ltd.. Active years: 2012-2016.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
2 out of 1,493 
1 out of 87 
1 out of 132,108 
Years Active: 2012-2016
Title: Hye Jin Jung: Innovator in Pharmaceutical Composition for Inhibiting Angiogenesis
Introduction
Hye Jin Jung is an accomplished inventor based in Seoul, South Korea, recognized for her significant contributions to the field of pharmaceutical science. With a portfolio that includes three patents, her innovations primarily focus on enhancing the efficacy of treatments for angiogenesis-related diseases.
Latest Patents
Hye Jin Jung's latest patents include groundbreaking pharmaceutical compositions aimed at inhibiting angiogenesis. The first patent details a pharmaceutical composition designed for this purpose, featuring a novel sulfonyl amide derivative compound. This compound is effective in preventing or treating diseases related to angiogenesis by selectively binding to UQCRB, thereby inhibiting biological functions without inducing apoptosis. Another notable patent offers a similar composition, utilizing an active ingredient that binds to QP-C. This innovation not only effectively prevents angiogenesis but also enhances drug safety by inhibiting cellular apoptosis.
Career Highlights
Throughout her career, Hye Jin Jung has worked with prestigious institutions such as the Industry-Academic Cooperation Foundation at Yonsei University and Samsung Electronics Co., Ltd. Her experience in these organizations has undoubtedly shaped her approach to research and innovation, leading to significant advancements in her field.
Collaborations
Her collaborative spirit is reflected in her work alongside esteemed colleagues including Ho Jeong Kwon and Jong Youn Lee. These partnerships have resulted in innovative solutions to complex health challenges, particularly in the area of angiogenesis, showcasing the importance of teamwork in scientific advancements.
Conclusion
Hye Jin Jung is a notable figure in the innovation landscape, particularly within pharmaceutical advances targeting angiogenesis. Her pioneering patents not only contribute to the medical community but also highlight her role as a leading inventor in South Korea. As she continues to push the boundaries of pharmaceutical science, her work is set to make a lasting impact on the treatment of angiogenesis-related diseases.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile